Supotaria
Generic Name
Supotaria 1 mg Oral Solution
Manufacturer
MediCare Pharma Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| supotaria 1 mg oral solution | ৳ 500.00 | N/A |
Description
Overview of the medicine
Supotaria 1 mg Oral Solution is an immunomodulating agent used for conditions requiring immune system modulation and anti-inflammatory effects.
Uses & Indications
Dosage
Adults
Typically 1 mg once daily. Dose may be adjusted based on patient response, tolerability, and severity of the condition, up to a maximum of 2 mg daily.
Elderly
Lower initial dose (e.g., 0.5 mg once daily) may be considered due to potential reduced renal and/or hepatic function. Careful monitoring is advised.
Renal_impairment
Use with caution in mild to moderate renal impairment. Dose reduction (e.g., 0.5 mg daily) may be necessary in severe renal impairment (CrCl < 30 ml/min). Consult physician.
How to Take
Take orally, with or without food. Use the provided calibrated measuring device (spoon or cup) for accurate dosing. Do not exceed the prescribed dose. Shake bottle well before use.
Mechanism of Action
Supotaria modulates specific immune pathways by binding to immune cell receptors, leading to a balanced immune response and reduction of pro-inflammatory cytokines.
Pharmacokinetics
Onset
Therapeutic effects may begin within 2-4 hours, with full clinical benefit observed after several days to weeks of regular dosing.
Excretion
Mainly excreted renally as metabolites (70%), with minor fecal excretion (30%).
Half life
Approximately 6-8 hours, with steady-state concentrations achieved within 2-3 days.
Absorption
Rapidly absorbed from the gastrointestinal tract, peak plasma levels reached within 1-2 hours.
Metabolism
Primarily hepatic metabolism via CYP450 enzymes (specifically CYP3A4 and CYP2D6), yielding active and inactive metabolites.
Side Effects
Contraindications
- Hypersensitivity to Supotaria or any of its excipients.
- Severe active infections (e.g., active tuberculosis, systemic fungal infections).
- Immunocompromised states where further immune suppression could be detrimental.
Drug Interactions
Live Vaccines
Avoid concomitant administration of live attenuated vaccines, as Supotaria may reduce vaccine efficacy and increase the risk of infection from the vaccine strain.
Immunosuppressants (e.g., Cyclosporine, Methotrexate)
May enhance immunosuppressive effects, leading to an increased risk of severe infections. Co-administration should be avoided or closely monitored.
CYP3A4 and CYP2D6 Inducers (e.g., Rifampin, Phenytoin)
May decrease Supotaria plasma concentrations, reducing its therapeutic efficacy.
CYP3A4 and CYP2D6 Inhibitors (e.g., Ketoconazole, Ritonavir)
May increase Supotaria plasma concentrations, requiring a dose reduction of Supotaria.
Storage
Store below 30°C in a dry place, protected from light and moisture. Do not freeze. Keep out of reach and sight of children.
Overdose
Symptoms of overdose may include severe immunosuppression, increased risk of opportunistic infections, and exacerbation of common side effects. In case of overdose, discontinue Supotaria immediately and initiate symptomatic and supportive treatment. There is no specific antidote.
Pregnancy & Lactation
Pregnancy Category C. Supotaria should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is unknown whether Supotaria is excreted in human milk; caution should be exercised when administered to a nursing mother. Consult a physician.
Side Effects
Contraindications
- Hypersensitivity to Supotaria or any of its excipients.
- Severe active infections (e.g., active tuberculosis, systemic fungal infections).
- Immunocompromised states where further immune suppression could be detrimental.
Drug Interactions
Live Vaccines
Avoid concomitant administration of live attenuated vaccines, as Supotaria may reduce vaccine efficacy and increase the risk of infection from the vaccine strain.
Immunosuppressants (e.g., Cyclosporine, Methotrexate)
May enhance immunosuppressive effects, leading to an increased risk of severe infections. Co-administration should be avoided or closely monitored.
CYP3A4 and CYP2D6 Inducers (e.g., Rifampin, Phenytoin)
May decrease Supotaria plasma concentrations, reducing its therapeutic efficacy.
CYP3A4 and CYP2D6 Inhibitors (e.g., Ketoconazole, Ritonavir)
May increase Supotaria plasma concentrations, requiring a dose reduction of Supotaria.
Storage
Store below 30°C in a dry place, protected from light and moisture. Do not freeze. Keep out of reach and sight of children.
Overdose
Symptoms of overdose may include severe immunosuppression, increased risk of opportunistic infections, and exacerbation of common side effects. In case of overdose, discontinue Supotaria immediately and initiate symptomatic and supportive treatment. There is no specific antidote.
Pregnancy & Lactation
Pregnancy Category C. Supotaria should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is unknown whether Supotaria is excreted in human milk; caution should be exercised when administered to a nursing mother. Consult a physician.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months from the manufacturing date when stored under recommended conditions. Once opened, use within 28 days.
Availability
Pharmacies nationwide
Approval Status
Approved by DGDA
Patent Status
Patent Pending
Clinical Trials
Ongoing Phase III clinical trials are investigating Supotaria's long-term efficacy and safety profile in patients with chronic autoimmune diseases and its potential role in modulating specific cancer immunotherapies.
Lab Monitoring
- Complete Blood Count (CBC) with differential before starting treatment and periodically (e.g., monthly) thereafter to monitor for neutropenia or other hematologic abnormalities.
- Liver function tests (LFTs) including ALT, AST, bilirubin, and alkaline phosphatase, before starting and every 3 months during treatment.
- Renal function tests (RFTs) including serum creatinine and BUN, periodically.
Doctor Notes
- Educate patients thoroughly on the signs and symptoms of infection and the importance of immediate reporting.
- Baseline and periodic laboratory monitoring (CBC, LFTs, RFTs) is essential to detect adverse effects early.
- Consider potential drug interactions, especially with other immunosuppressants and vaccines, and adjust therapy accordingly.
- Individualize dosing based on patient's response, tolerability, and underlying conditions.
Patient Guidelines
- Complete the full course of treatment as prescribed by your doctor, even if you feel better.
- Report any signs of infection (fever, chills, sore throat, persistent cough) immediately to your doctor.
- Do not share this medicine with others, even if they have similar symptoms.
- Store the solution properly as advised and use the measuring device provided.
Missed Dose Advice
If a dose is missed, take it as soon as you remember. If it is almost time for the next dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose to make up for a missed one.
Driving Precautions
Supotaria may cause dizziness or fatigue in some individuals. Exercise caution when driving or operating heavy machinery until you know how Supotaria affects your ability to perform such tasks.
Lifestyle Advice
- Maintain good personal hygiene, including frequent hand washing, to reduce the risk of infection.
- Avoid crowded places and contact with sick individuals during peak infection seasons.
- Discuss any vaccinations with your doctor before receiving them.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Supotaria Brand
Other medicines available under the same brand name
